Last updated: March 2, 2026
What Is the Case About?
Invitae Corporation filed a patent infringement lawsuit against Natera, Inc. in the United States District Court for the District of Delaware (D. Del., 1:21-cv-01635). The case pertains to genetic testing patents asserting that Natera's products infringe on Invitae’s intellectual property rights.
Summary of Claims and Defendants
Invitae alleges Natera infringes upon patents related to genetic testing methods. The patents involve methods of analyzing and interpreting genetic data, encompassing specific claims directed at processes used in non-invasive prenatal testing (NIPT). Natera disputes the allegations, denying infringement and challenging the validity of the patents.
Main patents involved include U.S. Patent Nos. 10,519,202 and 10,812,798, which are directed toward methods of detecting genetic variations in cell-free DNA.
Chronology of Litigation Events
| Date |
Event |
Description |
| March 5, 2021 |
Complaint Filed |
Invitae files suit alleging patent infringement. |
| May 2021 |
Natera’s Response |
Natera files motion to dismiss, contesting patent validity and non-infringement. |
| July 2021 |
Court Ruling |
Court denies motion to dismiss, proceeding to case merits. |
| January 2022 |
Discovery Phase |
Parties exchange documents and interrogatories. |
| June 2022 |
Summary Judgment Motions |
Both parties file motions arguing key issues of validity and infringement. |
| December 2022 |
Trial Readiness |
Case scheduled for trial, with ongoing discovery disputes. |
| April 2023 |
Settlement Discussions |
Informal talks held; no public resolution announced. |
Patent Validity and Freedom-to-Operate Considerations
Invitae claims the patents cover novel methods that give it a competitive advantage in genetic testing. Natera argues the patents lack novelty and are obvious, referencing prior art references. The validity of the patents hinges on prior art analysis and interpretation of patent claims, which courts scrutinize for obviousness, novelty, and written description.
Litigation Strategy and Potential Outcomes
- Invitae’s Strategy: Emphasizes patent infringement and aims for an injunction or damages. Likely to push for summary judgment on infringement claims if evidence is strong.
- Natera’s Defense: Focuses on invalidity of patents, possibly through invalidity arguments like prior art or indefiniteness. May pursue counterclaims or challenge the scope of patent claims.
- Potential Outcomes:
- Infringement Finding: Court could find Natera infringing, leading to damages, injunctions, or licensing.
- Invalidity Ruling: Court could invalidate patents, allowing Natera to continue product offerings.
- Settlement: Parties may negotiate licensing or settlement to avoid trial costs.
Market and Industry Implications
The case underscores patent turf battles in genetic testing, especially in NIPT. Successful infringement claims could influence product development, licensing negotiations, and patent strategies across the industry.
Comparison with Industry Trends
Patent litigation in genetic testing has increased over recent years, driven by technological advancements and market competition. Cases often involve issues of patent scope, prior art, and patent eligibility under 35 U.S.C. § 101.
| Aspect |
Industry Trend |
Case Insight |
| Patent Litigation |
Growing |
Invitae vs. Natera exemplifies this trend. |
| Patent Validity Challenges |
Common |
Validity disputes shape outcome. |
| Market Impact |
Significant |
Outcomes affect R&D and licensing. |
Court’s Disposition and Status
As of the latest update, case remains active with ongoing discovery and pretrial motions. No trial date has been announced. Both parties continue to litigate key issues.
Key Takeaways
- The case involves patent infringement claims centered on genetic testing methods used by Natera.
- Validity disputes focus on prior art and patent scope.
- The outcome may influence licensing and product deployment in NIPT.
- Patents involved are U.S. Patent Nos. 10,519,202 and 10,812,798.
- The case reflects broader industry patent battles within genetic testing sectors.
FAQs
Q1: What patents does Invitae allege are infringed?
A1: U.S. Patent Nos. 10,519,202 and 10,812,798.
Q2: What is Natera’s primary defense?
A2: Challenging the patents' validity, primarily arguing prior art renders the claims obvious.
Q3: What are the potential remedies if Invitae wins?
A3: Monetary damages, injunctive relief, or licensing agreements.
Q4: Has the case gone to trial yet?
A4: No, the case remains in pretrial phases with ongoing discovery and motions.
Q5: How does this case impact the genetic testing industry?
A5: It could influence patent enforcement strategies, licensing negotiations, and innovation practices.
References
[1] Invitae Corporation v. Natera, Inc., 1:21-cv-01635, U.S. District Court, District of Delaware.
